PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application

被引：5

作者：

Lekuona, Inaki ^{[1
]}

机构：

[1] Hosp Galdakao Usansolo OSI Barrualde, Serv Cardiol, Galdakao, Vizcaya, Spain

来源：

REVISTA ESPANOLA DE CARDIOLOGIA | 2018年 / 71卷 / 12期

关键词：

DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; COST-EFFECTIVENESS; TREATMENT GOALS; EVOLOCUMAB; RISK; ADOLESCENTS; ATTAINMENT; EZETIMIBE; OUTCOMES;

D O I：

10.1016/j.rec.2018.06.032

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：996 / 998

页数：3

共 19 条

[1] Inflammatory and Cholesterol Risk in the FOURIER Trial [J].

Bohula, Erin A. ;

Giugliano, Robert P. ;

Leiter, Lawrence A. ;

Verma, Subodh ;

Park, Jeong-Gun ;

Sever, Peter S. ;

Pineda, Armando Lira ;

Honarpour, Narimon ;

Wang, Huei ;

Murphy, Sabina A. ;

Keech, Anthony ;

Pedersen, Terje R. ;

Sabatine, Marc S. .

CIRCULATION, 2018, 138 (02) :131-140

[2] Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention [J].

Bohula, Erin A. ;

Morrow, David A. ;

Giugliano, Robert P. ;

Blazing, Michael A. ;

He, Ping ;

Park, Jeong-Gun ;

Murphy, Sabina A. ;

White, Jennifer A. ;

Kesaniemi, Y. Antero ;

Pedersen, Terje R. ;

Brady, Adrian J. ;

Mitchel, Yale ;

Cannon, Christopher P. ;

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (08) :911-921

[3] Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT [J].

Bohula, Erin A. ;

Giugliano, Robert P. ;

Cannon, Christopher P. ;

Zhou, Jing ;

Murphy, Sabina A. ;

White, Jennifer A. ;

Tershakovec, Andrew M. ;

Blazing, Michael A. ;

Braunwald, Eugene .

CIRCULATION, 2015, 132 (13) :1224-1233

[4] Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].

Bonaca, Marc P. ;

Nault, Patrice ;

Giugliano, Robert P. ;

Keech, Anthony C. ;

Pineda, Armando Lira ;

Kanevsky, Estella ;

Kuder, Julia ;

Murphy, Sabina A. ;

Jukema, J. Wouter ;

Lewis, Basil S. ;

Tokgozoglu, Lale ;

Somaratne, Ransi ;

Sever, Peter S. ;

Pedersen, Terje R. ;

Sabatine, Marc S. .

CIRCULATION, 2018, 137 (04) :338-350

[5] Treatment of Heterozygous Familial Hypercholesterolemia in Children and Adolescents: An Unsolved Problem [J].

Civeira, Fernando ;

Plana, Nuria .

REVISTA ESPANOLA DE CARDIOLOGIA, 2017, 70 (06) :423-424

[6]

Lima AOD, 2018, REV ESP CARDIOL, V71, P1027, DOI [10.1016/j.rec.2018.05.003, 10.1016/j.recesp.2018.02.013]

[7]

Garcia-Gil M Del Mar, 2011, Inform Prim Care, V19, P135

[8] Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting [J].

Korman, Max ;

Wisloff, Torbjorn .

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (01) :15-22

[9]

Ministerio de Sanidad Servicios Sociales e Igualdad, 2016, PTEVOLOCUMABV1030320

[10] Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up [J].

Perez de Isla, Leopoldo ;

Alonso, Rodrigo ;

Watts, Gerald F. ;

Mata, Nelva ;

Saltijeral Cerezo, Adriana ;

Muniz, Ovidio ;

Fuentes, Francisco ;

Luis Diaz-Diaz, Jose ;

de Andres, Raimundo ;

Zambon, Daniel ;

Rubio-Marin, Patricia ;

Barba-Romero, Miguel A. ;

Saenz, Pedro ;

Sanchez Munoz-Torrero, Juan F. ;

Martinez-Faedo, Ceferino ;

Miramontes-Gonzalez, Jose P. ;

Badimon, Lina ;

Mata, Pedro .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (11) :1278-1285

← 1 2 →